We’re still figuring out the side effects of GLP-1 weight-loss drugs

Research presented at an aging meeting found that overweight and diabetic GLP-1 users had biological-age measures around two to three years younger than comparable placebo users. The article also reviews potential adverse effects and says evidence on several risks remains mixed; dozens of patients are suing Novo Nordisk and Eli Lilly over alleged vision loss, which both companies dispute. GLP-1 use for weight loss rose to 11% of Americans from 3% in 2024, while WHO guidelines say it does not recommend medication for children under 10 because evidence on benefits and risks is lacking.

Analysis

The biological-age result is more valuable as a demand narrative than as evidence of a new indication today. A two-to-three-year shift in a biomarker does not establish longer life or improved outcomes; weight loss and improved metabolic health could explain the signal. Until trials show durable clinical benefit, it is unlikely to support a distinct longevity-market revenue case. The near-term commercial sensitivity is instead whether safety uncertainty changes persistence, prescribing, or payer willingness to cover treatment.

For LLY and NVO, adverse-event allegations and observational signals create asymmetric headline risk, but the article does not establish causality or quantify incidence. Litigation could still raise disclosure, labeling, and reputational costs before scientific resolution. Pediatric use is a longer-dated optionality, not a dependable growth driver: limited safety evidence and WHO caution for children under 10 constrain extrapolation, while growth and development outcomes may face a higher evidentiary bar than adult weight loss.

The contrarian point: investors may overreact to isolated safety headlines while underweighting the more consequential risk—if broader use brings lower persistence or tougher reimbursement, the commercial opportunity can disappoint without a definitive safety finding. Conversely, a biomarker story should not be capitalized as longevity economics absent outcomes data. No company-specific catalyst here justifies an LLY-versus-NVO relative-value call.

Key Decisions for Investors

• No trade on the biological-age announcement alone; avoid paying for a longevity premium until clinical-outcome data demonstrate benefit beyond weight and metabolic changes.
• For existing LLY/NVO exposure, monitor prescribing persistence, discontinuation, label changes, and payer coverage over the next 1–3 months; these would transmit safety concerns into revenue more directly than lawsuit headlines.
• Treat pediatric prescribing as a 6–18-month evidence and regulatory watch item, not a near-term growth thesis. Reassess if regulators or trial data establish age-specific safety and efficacy, particularly around growth and development.
• Falsify the cautious view if adequately controlled outcome studies show durable benefit with no material deterioration in discontinuation or coverage. Escalate downside concern if regulators impose meaningful label restrictions or companies revise guidance citing safety, persistence, or access.